Surgery: light – thermal – and electrical application – Light – thermal – and electrical application – Light application
Reexamination Certificate
2000-10-27
2003-02-25
Look, Edward K. (Department: 3754)
Surgery: light, thermal, and electrical application
Light, thermal, and electrical application
Light application
C606S004000, C606S006000
Reexamination Certificate
active
06524330
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a composition and method to treat abnormal blood vessel proliferation in the eye.
BACKGROUND OF THE INVENTION
Many therapeutic treatments of pathological conditions involve selective targeting of specific tissues or cells for destruction. For example, a goal in cancer therapy is to destroy only malignant cells while leaving normal cells undisturbed. As another example, a goal in ophthalmology is to destroy new abnormal blood vessels in the eye that can result in visual impairment if allowed to proliferate, while leaving normal existing blood vessels intact.
In the mammalian eye, macular degeneration (also called age related macula degeneration, AMD) is a pathological condition that results in proliferation of new blood vessels in the subretinal area. The new blood vessels proliferate from the choriocapillaris through defects in Bruch's membrane beneath or on top of retinal pigment epithelium (RPE), and form vascular membranes. While the presence of the new vessels themselves is not problematic, new vessels leak blood and other serous fluid which accumulate in surrounding spaces. It is this fluid accumulation that leads to visual impairment. For example, in the retina, both the large vessels and the capillaries normally have intact vessel walls. In the choroid, the large vessels normally have intact vessel walls, but the capillary walls or membranes contain fenestrations or openings. Any endogenous or exogenous fluid present in these capillaries, for example, blood, serous fluid, solubilized drug, etc. will leak outside the vessels and into the surrounding area. The accumulation of fluid can result in serous and hemorrhagic detachment of the RPE and neurosensory retina, and can lead to loss of vision due to fibrous deform scarring. More than 90% of cases having significant loss of central vision in AMD are attributed to choroidal neovascularization and the resulting exudation and scarring. Choroidal neovascularization occurs in about 8-10% of all patients with AMD, and is also seen in patient with pathologic myopia and presumed ocular histoplasmosis syndrome, as well as other idiopathic conditions.
Simply put, control of blood vessels is a way to treat certain pathological conditions such as macular degeneration. Macular degeneration results in new, inherently “leaky”, blood vessels in the eye. These new leaky vessels allow fluid to escape and pool in the surrounding tissues. The accumulation of fluid results in scar formation which can damage the eye and lead to altered vision. A goal is to destroy the new abnormal blood vessels and/or to prevent their growth.
Thus, a method to prevent or control the growth of subretinal blood vessels is needed. Such a method will in turn protect vision by protecting retinal integrity.
Summary of the Invention
The invention is directed to a therapeutic method to treat or prevent abnormal blood vessel formation and proliferation. Such an invention is useful in a variety of pathological conditions, for example, abnormal blood vessels in the eye as occurs in macular degeneration.
The method uses hypocrellin compounds. A member of the hypocrellin class of compounds is administered to reach the vessel and is photoactivated in the vessel. The hypocrellin class includes hypocrellin A, hypocrellin B, and derivatives such as amino-substituted hypocrellin B.
This invention will be further described in the following figure, detailed description and example.
REFERENCES:
patent: 5514714 (1996-05-01), Meruelo et al.
patent: 5576013 (1996-11-01), Williams et al.
patent: 5707986 (1998-01-01), Miller et al.
patent: 5952311 (1999-09-01), Kraus et al.
patent: 6001882 (1999-12-01), Fox et al.
Zhenjun Diwu,Novel Therapeutic and Diagnositc Applications of Hypocrellins and Hypericins,Photochemistry and Photobiology (Invited Review), vol. 61: No. 6, pp. 529-539, 1995.
Diwu et al.,Photosensitization with anticancer agents 18 perylenequinonoid pigments as potential photodynamic therapeutic agents: preparation and photodynamic properties of amino-substituted hypocrellin derivatives,Anti-Cancer Drug Design, vol. 8, 129-143, 1993.
Diwu et al.,Hypocrellins and their use in photosensitization,Photochemistry and Photobiology, vol. 52: No. 3, 609-616, 1990.
Diwu and Lown,Photosensitization with anticancer agents 16. The photo-oxidation of hypocrellin A. A mechanism study using 18-O labeling.,J. Photochem. Photobiol. B: Biol., 18: pp. 145-154, 1993.
Diwu et al.,Design, synthesis and investigation of mechanisms of action of novel protein kinase C inhibitors: Perylenequinonoid pigments,Biochemical Pharmacology, vol. 47, No. 2, pp. 373-385, 1994.
Diwu et al.,Photosensitization by anticancer agents 21: New perylene-and aminonaphthoquinones,Free Radical Biology and Medicine, vol. 20, No. 4, 589-593, 1996.
Duran and Song,Hypericin and its photodynamic action,Photochemistry and Photobiology (Yearly Review), vol. 43, No. 6, pp. 677-680, 1986.
Ebermann et al.,Natural products form plants as potential drugs for the photodynamic destruction of tumor cells,Journal of Photochemistry and Photobiology B: Biology 36, pp. 95-97, 1996.
Estey et al.,Hypocrellins as photosensitive for photodynamic therapy: a screening evaluation and pharmacokinetic study,Cancer Chemother Pharmacol, vol. 37, 343-350, 1996.
Falk et al.,Lowest excited triplet states of hypericin and isohypericin,J. Photochem & Photobiology, vol. 20 (1993) 133-137.
Fox et al.,Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal transformed, and malignant T lymphocytes: Implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders,J. Infest. Dermatol. 111: 327-332, 1998.
Harris et al.,Hypericin inhibits cell growth and induces apoptosis in retinal pigment epithelial cells: possible involvement of protein kinase C,Current Eye Research, 15: 225-262, 1996.
Kimura et al.,Hypericin inhibits choroidal endothelial cell proliferation and cord formation in vitro.,Current Eye Research, 16: 967-972, 1977.
Lenci et al.,Spectroscopic and photoacoustic studies of hypericin embedded in liposomes as a photoreceptor model,Photochemistry and Photobiology, vol. 62, No. 1, pp. 199-204, 1995.
Gerald G. Miller et al.,Uptake kinetics and intracellular localization of hypocrellin photosensitizers for photodynamic therapy: a confocal microscopy study,Photochemistry and Photobiology, vol. 61, No. 6, 632-638, 1995.
Wang Nenghui and Zhang Zhiyi,Relationship between photosensitive activities and chemical structure of hypocrellin A and B,Photochemistry and Photobiology, vol. 14, 207-217, 1992.
Tahara et al.,The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy,Current Eye Research, vol. 19, No. 4, pp. 323-329, 1999.
Zang et al.,EPR-spin trapping kinetic studies of superoxide radicals produced by photosensitized hypocrellin A, a photodynamic therapeutic agent,Biochem. and Mol. Biol. International, vol. 38, No. 4, Apr. 1996.
Zang et al.,Generation of free radicals during photosensitization of hypocrellin A and their effects on cardiac membranes,Photochemistry and Photobiology, vol. 56, No. 4, 453-462, 1992.
Grinstead Robert
Khoobehi Bahram
Peyman Gholam
Look Edward K.
White Dwayne J.
Wood Herron & Evans L.L.P.
LandOfFree
Method of ocular treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of ocular treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of ocular treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3151372